Literature DB >> 27126369

Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector.

Martin Horst Dieter Neumann1, Helen Schneck1, Yvonne Decker1, Susanne Schömer1, André Franken1, Volker Endris2, Nicole Pfarr3, Wilko Weichert3,4,5, Dieter Niederacher1, Tanja Fehm1, Hans Neubauer1.   

Abstract

Circulating tumor cells (CTC) are rare cells which have left the primary tumor to enter the blood stream. Although only a small CTC subgroup is capable of extravasating, the presence of CTCs is associated with an increased risk of metastasis and a shorter overall survival. Understanding the heterogeneous CTC biology will optimize treatment decisions and will thereby improve patient outcome. For this, robust workflows for detection and isolation of CTCs are urgently required. Here, we present a workflow to characterize CTCs by combining the advantages of both the CellSearch® and the CellCelector™ micromanipulation system. CTCs were isolated from CellSearch® cartridges using the CellCelector™ system and were deposited into PCR tubes for subsequent molecular analysis (whole genome amplification (WGA) and massive parallel multigene sequencing). By a CellCelector™ screen we reidentified 97% of CellSearch® SKBR-3 cells. Furthermore, we isolated 97% of CellSearch® -proven patient CTCs using the CellCelector™ system. Therein, we found an almost perfect correlation of R2  = 0.98 (Spearman's rho correlation, n = 20, p < 0.00001) between the CellSearch® CTC count (n = 271) and the CellCelector™ detected CTCs (n = 252). Isolated CTCs were analyzed by WGA and massive parallel multigene sequencing. In total, single nucleotide polymorphisms (SNPs) could be detected in 50 genes in seven CTCs, 12 MCF-7, and 3 T47D cells, respectively. Taken together, CTC quantification via the CellCelector™ system ensures a comprehensive detection of CTCs preidentified by the CellSearch® system. Moreover, the isolation of CTCs after CellSearch® using the CellCelector™ system guarantees for CTC enrichment without any contaminants enabling subsequent high throughput genomic analyses on single cell level.
© 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:125-132, 2017. © 2016 American Institute of Chemical Engineers.

Entities:  

Keywords:  CellCelector™; CellSearch®; circulating tumor cells; single cell analysis

Mesh:

Substances:

Year:  2016        PMID: 27126369     DOI: 10.1002/btpr.2294

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  20 in total

1.  Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA).

Authors:  Raffaele Palmirotta; Domenica Lovero; Erica Silvestris; Claudia Felici; Davide Quaresmini; Paola Cafforio; Franco Silvestris
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

2.  Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion.

Authors:  Sophie Laget; Lucile Broncy; Katia Hormigos; Dalia M Dhingra; Fatima BenMohamed; Thierry Capiod; Magne Osteras; Laurent Farinelli; Stephen Jackson; Patrizia Paterlini-Bréchot
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

3.  Single-Cell Analysis of BRAFV600E and NRASQ61R Mutation Status in Melanoma Cell Lines as Method Generation for Circulating Melanoma Cells.

Authors:  Joseph W Po; Yafeng Ma; Alison W S Luk; David Lynch; Bavanthi Balakrishnar; Daniel Brungs; Farhad Azimi; Adam Cooper; Erin Saricilar; Vinay Murthy; Paul de Souza; Therese M Becker
Journal:  Methods Mol Biol       Date:  2021

4.  Improving single-cell transcriptome sequencing efficiency with a microfluidic phase-switch device.

Authors:  Baoyue Zhang; Hong Xu; Yuqing Huang; Weiliang Shu; Hongtao Feng; Jin Cai; Jiang F Zhong; Yan Chen
Journal:  Analyst       Date:  2019-12-02       Impact factor: 4.616

5.  Single-Cell Digital Lysates Generated by Phase-Switch Microfluidic Device Reveal Transcriptome Perturbation of Cell Cycle.

Authors:  Yan Chen; Joshua Millstein; Yao Liu; Gina Y Chen; Xuelian Chen; Andres Stucky; Cunye Qu; Jian-Bing Fan; Xiao Chang; Ava Soleimany; Kai Wang; Jiangjian Zhong; Jie Liu; Frank D Gilliland; Zhongjun Li; Xi Zhang; Jiang F Zhong
Journal:  ACS Nano       Date:  2018-04-18       Impact factor: 15.881

Review 6.  The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer.

Authors:  Joanna Kapeleris; Arutha Kulasinghe; Majid E Warkiani; Ian Vela; Liz Kenny; Kenneth O'Byrne; Chamindie Punyadeera
Journal:  Front Oncol       Date:  2018-08-14       Impact factor: 6.244

7.  The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.

Authors:  Mette Ø Agerbæk; Sara R Bang-Christensen; Ming-Hsin Yang; Thomas M Clausen; Marina A Pereira; Shreya Sharma; Sisse B Ditlev; Morten A Nielsen; Swati Choudhary; Tobias Gustavsson; Poul H Sorensen; Tim Meyer; David Propper; Jonathan Shamash; Thor G Theander; Alexandra Aicher; Mads Daugaard; Christopher Heeschen; Ali Salanti
Journal:  Nat Commun       Date:  2018-08-16       Impact factor: 14.919

8.  Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies.

Authors:  Yafeng Ma; Alison Luk; Francis P Young; David Lynch; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Therese M Becker
Journal:  Int J Mol Sci       Date:  2016-08-04       Impact factor: 5.923

9.  A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer.

Authors:  Rita Lampignano; Liwen Yang; Martin H D Neumann; André Franken; Tanja Fehm; Dieter Niederacher; Hans Neubauer
Journal:  Int J Mol Sci       Date:  2017-08-31       Impact factor: 5.923

10.  Novel millimeter-wave-based method for in situ cell isolation and other applications.

Authors:  Barney Boyce; Natalia Samsonova
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.